Share

    


In This Section

Home / Blurb / Discussion List

Information on Keytruda Dosing & Testing Requirements

Jul 3, 2019, 13:16 PM
URL:
On June 17, 2019, the U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab (Keytruda, Merck) for patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy.

Information on Dosing and Testing Requirements for Keytruda (pembrolizumab) is available here.

Posted 7/2/2019

Leave a comment